Knowing what the receptor occupancy is in no way vital to knowing what the efficacy of leronlimab is. The efficacy stands on its own. Which is why you can tell the FDA is giving us the run around. Instead of bowing down to the FDA Cytodyn needs to sue them. Let an independent board look at the data and when they find it is not deficient throw that burning pile of trash that the FDA calls a decision right back in their laps.